» Articles » PMID: 35399168

Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms

Abstract

Background: Some prognostic factors for pancreatic neuroendocrine neoplasms (PanNENs) have been reported; however, the significance of lymphatic, microvascular, and perineural invasion remains unclear. We aimed to clarify the role of these factors in PanNEN recurrence.

Patients And Methods: We analyzed 138 patients who underwent curative pancreatectomy and were pathologically diagnosed with PanNEN. We evaluated the association between clinicopathological factors and the recurrence of PanNENs.

Results: The numbers of patients with lymphatic, microvascular, and perineural invasion were 34 (25%), 43 (31%) and 17 (12%), respectively. Twenty-four patients (17%) had recurrences, and the 3, 5, and 10-year recurrence-free survival (RFS) rates were 88%, 84%, and 76%, respectively. The recurrence sites (with duplication) were mainly the liver (twenty-two patients), followed by the lymph nodes (seven patients), and bone (two patients). In multivariate analyses, grade 2-3 and the presence of microvascular invasion were significant risk factors for RFS (hazard ratio=7.5 and 7.9, respectively). When examining outcomes according to these factors, the 5-year RFS rates of patients with risk scores of 0, 1, and 2 were 100%, 91%, and 32%, respectively (p<0.001). Even in patients with grade 1 (n=97) or limited resection (enucleation, splenic-preserving distal pancreatectomy, central pancreatectomy, and duodenum-preserving pancreatic head resection, n=62), the presence of microvascular invasion was a significant risk factor for RFS (hazard ratio=13.4 and 18.0, respectively).

Conclusion: The presence of microvascular invasion is an independent risk factor for recurrence in patients with PanNEN.

Citing Articles

Evaluation of the details and importance of lymphatic, microvascular, and perineural invasion in patients with non-functioning pancreatic neuroendocrine neoplasms based on tumor size and the 2022 World Health Organization classification: a 23-year....

Izumo W, Kawaida H, Saito R, Nakata Y, Amemiya H, Maruyama S World J Surg Oncol. 2025; 23(1):79.

PMID: 40055716 PMC: 11889744. DOI: 10.1186/s12957-025-03734-0.


Influence of Lymphatic, Microvascular and Perineural Invasion on Oncological Outcome in Patients with Neuroendocrine Tumors of the Small Intestine.

Butz F, Dukaczewska A, Kunze C, Kromer J, Reinhard L, Jann H Cancers (Basel). 2024; 16(2).

PMID: 38254794 PMC: 10813650. DOI: 10.3390/cancers16020305.


Prediction of the lymphatic, microvascular, and perineural invasion of pancreatic neuroendocrine tumors using preoperative magnetic resonance imaging.

Liu Y, Zhu H, Chen M, Sun W, Li X, Sun Y World J Gastrointest Surg. 2024; 15(12):2809-2819.

PMID: 38222000 PMC: 10784819. DOI: 10.4240/wjgs.v15.i12.2809.

References
1.
Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y . A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2013; 259(4):773-80. DOI: 10.1097/SLA.0000000000000263. View

2.
Harimoto N, Hoshino K, Muranushi R, Hagiwara K, Yamanaka T, Ishii N . Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages. Pancreatology. 2019; 19(6):897-902. DOI: 10.1016/j.pan.2019.08.003. View

3.
Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

4.
Doi R . Determinants of surgical resection for pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2015; 22(8):610-7. DOI: 10.1002/jhbp.224. View

5.
Genc C, Jilesen A, Partelli S, Falconi M, Muffatti F, van Kemenade F . A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg. 2017; 267(6):1148-1154. DOI: 10.1097/SLA.0000000000002123. View